Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Endo International plc (ENDP)

0.3744   0.007 (1.99%) 08-15 16:00
Open: 0.39 Pre. Close: 0.3671
High: 0.3976 Low: 0.37
Volume: 20,613,041 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:20:14 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.34     One year: 0.35
Support: Support1: 0.28    Support2: 0.23
Resistance: Resistance1: 0.29    Resistance2: 0.3
Pivot: 0.29
Moving Average: MA(5): 0.29     MA(20): 0.29
MA(100): 0.31     MA(250): 1.62
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 47.4     %D(3): 47.4
RSI: RSI(14): 69.7
52-week: High: 6.03  Low: 0.08
Average Vol(K): 3-Month: 24,544 (K)  10-Days: 43,183 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ENDP ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.31 - 0.31 0.31 - 0.31
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.29 - 0.29 0.29 - 0.3

Company Description

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Headline News

Mon, 06 Mar 2023
North American Morning Briefing : Focus This Week -3- - Marketscreener.com

Mon, 06 Mar 2023
Endo International : ENDP Q4 2022 Slides - Marketscreener.com

Thu, 23 Feb 2023
Novartis to pay $30 mln to health plans, consumers over Exforge ... - Reuters

Mon, 29 Aug 2022
ENDO INTERNATIONAL PLC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Tue, 16 Aug 2022
Endo Enters Into Restructuring Support Agreement with Senior ... - PR Newswire

Wed, 03 Aug 2022
Endo International sees 23% rise on 3x higher than normal volume ... - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 234 (M)
Shares Float 199 (M)
% Held by Insiders 0.7 (%)
% Held by Institutions 83.6 (%)
Shares Short 41,450 (K)
Shares Short P.Month 32,790 (K)

Stock Financials

EPS 0.78
EPS Est Next Qtl 0.7
EPS Est This Year 3.51
EPS Est Next Year 3
Book Value (p.s.) -2.81
Profit Margin (%) -24.9
Operating Margin (%) 24.7
Return on Assets (ttm) 5.1
Return on Equity (ttm) 0
Qtrly Rev. Growth -9.2
Gross Profit (p.s.) 7.61
Sales Per Share 12.53
EBITDA (p.s.) 3.05
Qtrly Earnings Growth 0
Operating Cash Flow 369 (M)
Levered Free Cash Flow 639 (M)

Stock Valuations

PE Ratio 0.37
PEG Ratio -0.1
Price to Book value -0.11
Price to Sales 0.02
Price to Cash Flow 0.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.